Breaking News

WuXi Biologics, Adagene Enter Strategic Development and Mfg. Pact

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and Adagene Inc., an emerging biotech company developing antibody therapeutics, entered a strategic collaboration to support supply of Adagene’s products for clinical trials under Investigational New Drug (IND) applications in both China and the U.S. Adagene has an internal pipeline of antibody therapeutics focused on difficult antigens, and therapeutic candidates with enhanced biophysical properties.   “The strategic collaboration with WuXi Biologics will enable Ad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters